News

Hosted on MSN2mon
H.C. Wainwright sets $16 target on Astria Therapeutics stock
The firm's decision follows Astria's announcement of the initiation of a Phase 1a study for STAR-0310, a monoclonal antibody and OX40 antagonist, aimed at treating atopic dermatitis and ...
GlobalData on MSN1mon
Astria commences Phase III hereditary angioedema therapy trial
The decision to advance to Phase III trials was based on the promising final top-line results from the Phase Ib/II ALPHA-STAR ...
Morningstar26d
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Astria Therapeutics, Inc. (Nasdaq ... Our lead program, navenibart (STAR-0215), is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary ...